Skip to main content
SpringerLink
Log in

Adalimumab/etanercept/secukinumab

Myasthenia gravis and lack of efficacy: 3 case reports

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Greco G, et al. Controversial role of anti-TNF alpha and anti-interleukin monoclonal antibodies (mAbs) in patients with Myasthenia Gravis and rheumatologic comorbidities. Acta Myologica 41 (Suppl. 1): 67, No. 3, Sep 2022. Available from: URL: http://doi.org/10.36185/2532-1900-074 [abstract]

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Adalimumab/etanercept/secukinumab. Reactions Weekly 1932, 24 (2022). https://doi.org/10.1007/s40278-022-27389-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-27389-0

Search

Navigation